Startseite
Kongressberichte 2021
58th Annual Meeting of the American Society of Hematology
Choice of ASH presentations
653. Myeloma
Saturday, December 3, 2016: 4:00 PM-5:30 PM
653. Myeloma: Therapy, excluding Transplantation: Clinical Studies, Minimal Residual Disease, and Biomarkers
Thierry Facon, Meletios Dimopoulos, Angela Dispenzieri, John V. Catalano, et al.
Pieter Sonneveld, Meral Beksac, Bronno van der Holt, Meletios A. Dimopoulos, et al.
Conclusions: Consolidation treatment with VRD followed by Lenalidomide maintenance until progression or toxicity shows promising results as compared to maintenance alone for younger NDMM pts, but further study follow-up is needed.
Alessandra Di Bacco, Nizar J. Bahlis, Nikhil C Munshi, Hervé Avet-Loiseau, et al.
Conclusions: In TOURMALINE-MM1, c-MYC expression was higher in MM tumor samples from pts with 2-3 vs 1 prior therapies. The IRd regimen was active in c-MYC-high and c-MYC-low pts, but its impact on PFS vs placebo-Rd was greater in c-MYC-high pts, thus providing a potential explanation for the enhanced PFS benefit with IRd vs placebo-Rd in pts with 2-3 prior therapies. The PFS benefit with IRd in c-MYC-low pts with 2-3 prior lines suggests that, in advanced MM, further genomic alterations may also be contributing to ixazomib sensitivity.
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, David A Cairns, et al.
Conclusion: For the first time we have shown that the use of a response-adapted therapy based on the use of chemotherapeutic agents with a different mode of action in myeloma can improve response rates, both pre- and post-transplant and that these translate into improved PFS.
Ruth Mary de Tute, Andy C Rawstron, David A Cairns, Charlotte Pawlyn, Roger G Owen, et al.
Hervé Avet-Loiseau, Tineke Casneuf, Christopher Chiu, Jacob P. Laubach, et al.
Conclusion: These two studies represent the first randomized, controlled, prospective evaluation of MRD in the RRMM phase 3 clinical trial setting and demonstrate that DARA-containing therapies are able to drive patients to remarkably deep levels of clinical response. Regardless of the SOC component, DARA-containing regimens consistently demonstrated ≥3-fold increase in MRD negative rate compared with the control groups at all evaluated thresholds. Importantly, since patients who achieved MRD negative status demonstrated low PFS event rates, the deep clinical responses induced by DARA may lead to improved survival.
Poster: Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma
A Phase 2 Study Investigating Efficacy and Safety
David S. Siegel, Gary J. Schiller, Kevin W. Song, Richy Agajanian, et al.
Conclusions:
- MM-014 is the first prospective clinical trial evaluating a POM-based doublet or triplet combination sequenced immediately after pts became refractory to LEN-based therapy in the first or second line.
- This updated analysis of the MM-014 trial demonstrates the safety and efficacy of POM + LoDEX in pts who require third-line therapy following last prior Tx with LEN.
- Rates of hematologic AEs were lower compared with previous studies evaluating POM + LoDEX in pts with RRMM.
- Immune subset analyses confirmed the persistent T-cell stimulatory activity of POM following prior exposure to LEN.
- Results support the use of POM + LoDEX immediately after LEN-based therapy to treat pts with RRMM.
- POM + LoDEX was active, with 86% of pts having at least disease stabilization, suggesting that pts could benefit from the addition of a mechanistically synergistic active agent.
- Future analyses will include a cohort of pts treated with POM + LoDEX + daratumumab immediately after pts become refractory to LEN-based therapy in the first or second line.